Spyre Therapeutics, Inc. Common Stock (SYRE) Stock
NASDAQ · SYRE
Key stats
- Market cap
- $10.14B
- Price / Earnings ratio
- -37.6x
- EPS (TTM)
- -$2.78
- Volume
- Loading
- 52-week high
- $110.64
- 52-week low
- $21.63
Source: third-party data provider, as of November 13, 2026
Compare with SYRE
Recent news

Zacks Investment Research
Spyre's Anti-IL-23 Antibody Meets Goal in Ulcerative Colitis Study
SYRESeptember 9, 2026
Zacks Investment Research
Spyre's Anti-IL-23 Antibody Meets Goal in Ulcerative Colitis Study
SYRE

Zacks Investment Research
Spyre Therapeutics (SYRE) Down 16.6% Since Last Earnings Report: Can It Rebound?
SYRESeptember 3, 2026
Zacks Investment Research
Spyre Therapeutics (SYRE) Down 16.6% Since Last Earnings Report: Can It Rebound?
SYRE

Zacks Investment Research
SYRE Stock Sinks After Mixed SKYWAY Study Data in Rheumatoid Arthritis
SYREAugust 26, 2026
Zacks Investment Research
SYRE Stock Sinks After Mixed SKYWAY Study Data in Rheumatoid Arthritis
SYRE

Investors Business Daily
Spyre Plunges, While This Setback Isn't Shaking Analysts
SYREAugust 26, 2026
Investors Business Daily
Spyre Plunges, While This Setback Isn't Shaking Analysts
SYRE
Technical indicators
- RSI 14
- 64.24
- MACD 12/26/9
- 4.45
- EMA 9 of MACD
- 3.18
- MACD histogram
- 1.27
- SMA 50
- $90.83
- Price above SMA 50
- EMA 50
- $93.75
- Price above EMA 50
- SMA 200
- $75.97
- Price above SMA 200
- EMA 200
- $72.94
- Price above EMA 200
Calculated by Gotrade from daily closing prices, as of November 11, 2026. Technical data, not a recommendation.
Analyst ratings
Analyst consensus: Buy
Based on 6 analyst ratings
Strong Sell0
Sell0
Hold0
Buy6
Strong Buy0
Third-party analyst opinion, not a recommendation from Gotrade.
Financials
Performance
Revenue
Net income
Net margin %
2021
2022
2023
2024
2025
22M15M7M0
Debt & Balance Sheet
Total assets
Total liabilities
2021
2022
2023
2024
2025
933M616M308M0
Revenue to Profit
2025$0.0
Revenue$0.0
Cost of revenue$0.0
Gross profit$0.0
Operating expenses$-155.2M
Net incomeEarnings
No data available
Source: third-party data provider
Latest news

Zacks Investment Research
Spyre's Anti-IL-23 Antibody Meets Goal in Ulcerative Colitis Study
SYRESeptember 9, 2026
Zacks Investment Research
Spyre's Anti-IL-23 Antibody Meets Goal in Ulcerative Colitis Study
SYRE

Zacks Investment Research
Spyre Therapeutics (SYRE) Down 16.6% Since Last Earnings Report: Can It Rebound?
SYRESeptember 3, 2026
Zacks Investment Research
Spyre Therapeutics (SYRE) Down 16.6% Since Last Earnings Report: Can It Rebound?
SYRE

Zacks Investment Research
SYRE Stock Sinks After Mixed SKYWAY Study Data in Rheumatoid Arthritis
SYREAugust 26, 2026
Zacks Investment Research
SYRE Stock Sinks After Mixed SKYWAY Study Data in Rheumatoid Arthritis
SYRE

Investors Business Daily
Spyre Plunges, While This Setback Isn't Shaking Analysts
SYREAugust 26, 2026
Investors Business Daily
Spyre Plunges, While This Setback Isn't Shaking Analysts
SYRE

Zacks Investment Research
Can Spyre's SPY772 HS Study Broaden Its Growth Story Beyond Core IBD?
SYREAugust 24, 2026
Zacks Investment Research
Can Spyre's SPY772 HS Study Broaden Its Growth Story Beyond Core IBD?
SYRE

Zacks Investment Research
Is SYRE a Buy Now as Clinical Catalysts Clash With Valuation Risk?
SYREAugust 24, 2026
Zacks Investment Research
Is SYRE a Buy Now as Clinical Catalysts Clash With Valuation Risk?
SYRE

Zacks Investment Research
SYRE Rallies 44.9% in 3 Months. Can Clinical Catalysts Sustain It?
SYREAugust 24, 2026
Zacks Investment Research
SYRE Rallies 44.9% in 3 Months. Can Clinical Catalysts Sustain It?
SYRE

Zacks Investment Research
SYRE's Q2 Loss Narrower Than Expected, Pipeline Progresses
SYREAugust 5, 2026
Zacks Investment Research
SYRE's Q2 Loss Narrower Than Expected, Pipeline Progresses
SYRE

Zacks Investment Research
Is SYRE Stock a Buy Now or a Wait-and-See Biotech Story Today
SYREJune 29, 2026
Zacks Investment Research
Is SYRE Stock a Buy Now or a Wait-and-See Biotech Story Today
SYRE

Zacks Investment Research
Spyre Therapeutics Stock Outlook Hinges on 2026 Study Catalysts
SYREJune 29, 2026
Zacks Investment Research
Spyre Therapeutics Stock Outlook Hinges on 2026 Study Catalysts
SYRE
About Spyre Therapeutics, Inc. Common Stock
No description available.
SectorHealthcare
IndustryBiotechnology
Employees125
CEODr. Cameron Turtle DPHIL, Ph.D.
IPO DateApr 6, 2016
HeadquartersWaltham, MA
Key Executives
| Name | Title | Year Born |
|---|---|---|
| Dr. Cameron Turtle DPHIL, Ph.D. | CEO & Director | 1990 |
| Mr. Scott L. Burrows | Chief Financial Officer | 1977 |
| Ms. Heidy Abreu King-Jones J.D., L.L.M. | Chief Legal Officer & Corporate Secretary | 1983 |
| Dr. Sheldon Sloan M.B.E., M.D. | Chief Medical Officer | 1959 |
| Dr. Janet Gunzner-Toste M.B.A., Ph.D. | Senior Vice President of Operations | — |
| Mr. Brian Connolly | Chief Technical Officer | — |
| Mr. Eric McIntyre | Senior Vice President of Finance & Investor Relations | — |
| Mr. James Myers | Senior Vice President of Quality & Compliance | — |
| Dr. Justin LaFountaine Ph.D. | Senior Vice President of Corporate Development | — |
| Ms. Melissa Cooper | Senior Vice President of People | — |
Fundamentals
Valuation
Price-to-book value9.44
Profitability
Return on Equity-30.00%
Return on Assets-28.00%
EBITDA$-263.86M
Trading
Average volume1,076,458
Source: third-party data provider, as of November 13, 2026
Technical indicators
- RSI 14
- 64.24
- MACD 12/26/9
- 4.45
- EMA 9 of MACD
- 3.18
- MACD histogram
- 1.27
- SMA 50
- $90.83
- Price above SMA 50
- EMA 50
- $93.75
- Price above EMA 50
- SMA 200
- $75.97
- Price above SMA 200
- EMA 200
- $72.94
- Price above EMA 200
Calculated by Gotrade from daily closing prices, as of November 11, 2026. Technical data, not a recommendation.
Analyst views
6 analyst ratings
Third-party analyst opinion, not a recommendation from Gotrade.
Analyst consensus:Buy
100% Buy
0% Hold
0% Sell
Analyst price target
- Low
- $110.00
- Average
- $122.17
- High
- $135.00
Seasonality
Monthly price change (%)| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2023 | +28.7 | +9.9 | ||||||||||
| 2024 | +21.1 | +6.1 | +26.9 | -10.7 | +3.2 | -36.1 | +12.0 | +6.8 | +10.6 | +18.5 | -16.3 | -15.8 |
| 2025 | -3.6 | -14.0 | -10.0 | -0.5 | +4.2 | -2.8 | +9.6 | +1.4 | +0.8 | +48.6 | +26.2 | +14.3 |
| 2026 | +4.6 | +31.3 | +18.7 | +52.2 | +5.9 | +25.9 | +10.6 | -5.9 | +0.6 | +7.4 | +9.4 |
Compare stocks
Market cap
$10.14B
-
-
-
Price / Earnings ratio
-37.60
-
-
-
Price / Sales ratio
-
-
-
Dividend yield
0.00%
-
-
-
Average volume
1,076,458
-
-
-
Earnings per share
$-2.78
-
-
-



